New York Investor Access Program
Three Private Evenings.
One Complete PathFree Presentation Each Night.
Direct CEO Access to PathFree Technologies and AiMediQ™ powered by datasyteAI™
PathFree Technologies has engaged Borex Capital to organize a three-evening New York investor presentation and Q&A program conducted in private dinner settings.
Dr. Perry M. Brunette, Ph.D., CEO & Founder, will personally present PathFree Technologies, introduce AiMediQ™ powered by datasyteAI™, explain the investment opportunity, and answer questions from each invited investor group.
- Private Presentation Evenings
- 03Private Presentation Evenings
- Targeted Invitations Per Evening
- 30Targeted Invitations Per Evening
- Targeted Invitations Across the Program
- 90Targeted Invitations Across the Program
Invitation figures are targets. Actual attendance, investor engagement, diligence activity, commitments, and investment outcomes may differ and are not guaranteed.
Quick Access
Everything, one tap away
- Request InformationStart here — ask for the investor package
- View the PresentationTransforming Cardiac Care Through AI
- The CompanyWho PathFree is
- The TechnologyAIMediQ platform
- The EveningsThree presentations in New York
- The OfferingWhat is being offered
- EconomicsHow the numbers work
- RisksWhat could go wrong
- QuestionsAnswers to common questions
Campaign Thesis
Why This Campaign. Why New York. Why Now.
Capital formation is still built on trust.
Large capital raises rarely begin with a form submission. They begin with focused conversations, informed questions, direct access to leadership, and a room built around the opportunity.
The PathFree Investor Dinner Campaign is designed to compress months of fragmented introductions into three concentrated evenings in New York—giving qualified prospective investors direct access to the company, its leadership, its technology, and its capital strategy.
- Access
- Direct engagement with a targeted investor audience.
- Focus
- PathFree is the sole presenting company during the series.
- Momentum
- Structured follow-up designed to move qualified interest into diligence.
The Problem
Cardiac arrest is not primarily a treatment problem. It is a timing problem.
Out-of-hospital cardiac arrest remains one of the most lethal medical events precisely because the decisive minutes occur before clinical care arrives. Survival falls sharply with every minute of delay in recognition, response, and defibrillation.
Recognition is delayed
Collapse is frequently unwitnessed, misread, or reported late. The clock begins before anyone realizes the clock has begun.
Response is uneven
Bystander intervention rates vary widely by geography, building type, and time of day. Access to a functioning defibrillator is inconsistent and rarely verified.
Information arrives last
Responding clinicians typically receive the least data at the moment they need the most. Pre-arrival context is fragmented across callers, dispatch, and devices.
Post-event learning is lost
Without a structured data layer, each event teaches the system almost nothing. Response quality does not compound.
The Clinical Problem
In cardiac arrest, every second competes with complexity.
Current Environment
Simultaneous demands, fragmented inputs.
- High-pressure Code Blue response
- Multiple disconnected monitors
- Paper or manual protocols
- Medication timing pressure
- Scattered documentation
- Visible cognitive load
Intelligently Supported Environment
One coordinated picture of the event.
- Calm clinical coordination
- Real-time protocol state
- Timing prompts
- Rhythm information
- Medication checks
- Role guidance
- Automated event documentation
Even experienced clinical teams must process rapidly changing patient data, protocol steps, medication timing, equipment readiness, communication, and documentation at the same time.
PathFree is developing technology intended to reduce fragmentation and help clinicians maintain clarity during high-pressure emergency workflows.
Illustrative depiction of intended product concept. Development-stage technology; no clinical outcome, performance, or error-reduction claims are made.
The Platform
AIMediQ™, powered by datasyteAI™
AIMediQ™ is PathFree's emergency cardiac-response system. It is powered by datasyteAI™, the company's clinical intelligence and data layer.
Detect
Signal capture and event recognition intended to shorten the gap between physiological collapse and system awareness.
Guide
Structured, step-sequenced intervention guidance designed for untrained and semi-trained responders under extreme stress.
Coordinate
Device readiness, responder routing, and pre-arrival context delivered to the people converging on the event.
Learn
datasyteAI™ structures each event into a reviewable record, so protocol quality compounds across the network rather than resetting.
Capital-Access Engagement
PathFree Technologies · Engagement with Borex Capital
PathFree Technologies has engaged Borex Capital to organize and facilitate a three-evening New York investor presentation program.
Borex Capital
- Organizes and coordinates the private dinner settings
- Identifies and invites targeted prospective investors
- Facilitates introductions between PathFree and invitees
- Coordinates applicable event logistics
- Distributes PathFree-approved presentation materials
- Conducts appropriate post-event follow-up
- Supports the introduction process
PathFree Technologies
- Serves as the sole presenting company
- Provides all approved investor materials
- Presents the company and investment opportunity
- Presents AiMediQ™ powered by datasyteAI™
- Conducts the product discussion or walkthrough
- Answers investor questions
- Controls company, clinical, regulatory, product, and offering statements
- Conducts management follow-up and diligence
- Accepts or rejects investments under the definitive offering documents
Prospective Investors
- Attend voluntarily
- Review the information presented
- Ask questions and request additional materials
- Conduct their own diligence
- Consult their own advisers
- Make their own independent investment decisions
Borex Capital serves as an organizer and investor-introduction facilitator. Borex Capital is not a guarantor of attendance, investor interest, diligence, commitments, or capital formation. Prospective investors make independent investment decisions.
The Presentation Program
Direct Access to the Founder and CEO
The presentation is delivered by Dr. Perry M. Brunette, Ph.D., CEO & Founder of PathFree Technologies.
Investors hear the PathFree story directly from the company’s leadership—not through a third-party presenter. Dr. Brunette will explain the clinical need, introduce the company’s flagship technology, discuss the business and capital strategy, and respond directly to investor questions.
Founder-Led Presentation
The company’s vision is presented directly by its CEO and Founder.
Flagship Product Focus
AiMediQ™ powered by datasyteAI™ is the central technology presentation.
Direct Questions
Invitees may address company and offering questions directly to PathFree leadership.
Clear Next Steps
Interested prospective investors may request approved follow-up materials and diligence access.
PathFree Technologies is the sole presenting company. Dr. Perry M. Brunette, Ph.D., CEO & Founder, is expected to lead the company presentation and investor Q&A.
The Campaign Capital
Up to $50,000 in campaign capital
PathFree Technologies is offering a limited campaign-capital investment opportunity intended to fund the execution of its three-evening New York investor presentation series.
$50K
Maximum campaign capital
Aggregate, across the campaign
Equity
Ownership component
Common equity in PathFree Technologies Corporation
Contingent
Campaign Performance Right
Separate from equity. Payable only on defined milestones. Not guaranteed.
Second Series Trigger
If the full $50,000 maximum offering is raised, PathFree Technologies intends to announce a second three-night New York investor presentation series. The timing, venue, and format of any second series are subject to board approval, available resources, and market conditions.
Campaign Performance Right payments are contingent and are not guaranteed. No return of any kind is assured.
Series Multiplier
Why the Second Series Changes the Contingent-Payment Profile
The first three-evening series is designed to introduce PathFree to a targeted investor audience. If the full $50,000 campaign capital is raised, a second three-evening series would double the planned investor access runway—from three nights to six nights.
More qualified introductions
A second series means additional invited investor groups, management meetings, and diligence conversations. Each evening is an independent opportunity to meet investors who were not in the first room.
More time for decisions
Institutional and high-net-worth investment decisions rarely happen in a single evening. A second series extends the measurement window and gives prospective investors more time to review materials, conduct diligence, and discuss terms.
Higher milestone exposure
The Campaign Performance Right is driven by Qualified Raise Proceeds. Because the schedule scales from 0% below $500,000 up to 200% at $5 million or more, additional investor relationships increase the possibility of reaching the higher illustrative payment thresholds.
The second series is not a guarantee of higher proceeds or any payment. It is an expansion of opportunity: more nights, more relationships, and more chances for the campaign to reach the Qualified Raise Proceeds milestones that determine the contingent payment.
The Company
PathFree Technologies exists to compress the interval between cardiac collapse and clinical-grade intervention — the interval in which survival is decided.
Time is the therapy
Every operating decision at PathFree is measured against a single question: does it remove seconds from the response interval? Product scope, engineering priority, and vendor selection are all filtered through it.
Clinical rigour before commercial velocity
PathFree develops toward regulated clinical pathways. Claims are constrained to what evidence supports, and the roadmap is sequenced around validation, not announcement.
Infrastructure, not applications
The company builds durable layers — device intelligence, triage data, and response coordination — intended to sit beneath many care settings rather than serve a single one.
Discipline in capital
PathFree raises deliberately, in defined tranches, against defined milestones, and communicates the contingency of every forward-looking element.
Next Step
Confidential materials are provided only after review.
Qualified prospective investors may request the PathFree Technologies information package and details of the New York investor presentation series.